Dorra always adheres to R&D-driven strategy supported by a tri-wing business development encompassing manufacture, marketing and quality assurance, dedicated to the development and production green and highly efficient industrial compounds. We have established dual R&D centers in Nanjing and Taizhou conducting comprehensive work from laboratory research to pilot scale development. The manufacturing sites in Hubei province are approved by China GMP, IS09001,EU authorities, FDA, Japan PMDA, etc.
MORE
At present, Dorra has two R&D centers, Nanjing R&D Center and Taizhou R&D Center, which are located in Nanjing Jiangbei New District, the first national new district in Jiangsu Province, New Materials Life Science Park, and Taizhou City, Zhejiang Province, with a total area of 6000 square meters...
Dorra Pharma currently has three production bases which are located at the Grade D industrial Park in Hubei and Gansu Province with total reactor capacity of 3,000 m3. The quality system are approved by NMPA/PMDA/US FDA, offering key starting material, GMP intermediates, APIs and CDMO services.
MORE
Dorra Pharma is proud to announce that its self-developed core active ...
On June 24, 2025, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that Sephienc...
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號(hào)-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
